{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:19:37Z","timestamp":1761862777759},"reference-count":48,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T00:00:00Z","timestamp":1226275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Highly active antiretroviral therapy (HAART) is reported to cause insulin resistance among adults, but effects on children are less clear. We attempted to describe the prevalence of insulin resistance among HIV\u2010infected children receiving HAART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Insulin resistance was assessed at 96 weeks of treatment with nonnucleoside reverse transcriptase inhibitor (NNRTI)\u2010based HAART (nevirapine or efavirenz with stavudine and lamivudine) among children in Chiang Mai, Thailand. Insulin resistance was defined as homeostasis model assessment for insulin resistance (HOMA\u2010IR) \u22653.16, fasting c\u2010peptide \u22654.40\u2003ng\/mL or fasting insulin \u226525.0\u2003\u03bcU\/mL. Impaired fasting glucose (IFG) was defined as glucose \u2265110\u2003mg\/dL. Measurements were analysed for associations with age, lipodystrophy, treatment regimen and clinical data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of insulin resistance was 6.5%; no child had IFG. Those with insulin resistance were older with higher body mass index. Children \u226510 years had higher HOMA\u2010IR, c\u2010peptide and insulin, but no difference was seen in the frequency of insulin resistance. No associations between insulin resistance and lipodystrophy or treatment regimen were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Insulin resistance is uncommon among children receiving NNRTI\u2010based HAART and is unrelated to lipodystrophy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00653.x","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T01:36:04Z","timestamp":1226367364000},"page":"72-78","source":"Crossref","is-referenced-by-count":15,"title":["Low prevalence of insulin resistance among HIV\u2010infected children receiving nonnucleoside reverse transcriptase inhibitor\u2010based highly active antiretroviral therapy in Thailand"],"prefix":"10.1111","volume":"10","author":[{"given":"B","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Aurpibul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mangklabruks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/430714"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/510489"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318125720a"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199815000-00001"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907090-00001"},{"key":"e_1_2_6_9_2","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV\u20101 protease\u2010inhibitor\u2010associated lipodystrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr A","year":"1999","journal-title":"a cohort study"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200304001-00018"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.11.2444"},{"key":"e_1_2_6_12_2","first-page":"2039","article-title":"Insulin resistance during puberty","volume":"48","author":"Moran A","year":"1999","journal-title":"results from clamp studies in 357 children"},{"key":"e_1_2_6_13_2","first-page":"908","article-title":"Endocrine pancreatic dysfunction in HIV\u2010infected children","volume":"190","author":"Rondanelli M","year":"2004","journal-title":"association with growth alterations"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000247131.76584.af"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009290-00008"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200205000-00011"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200306130-00006"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000178930.93033.f2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0125"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000215003.32256.aa"},{"key":"e_1_2_6_21_2","first-page":"13","article-title":"Prevalence of lipodystrophy in HIV\u2010infected children","volume":"166","author":"Ene L","year":"2007","journal-title":"a cross-sectional study"},{"key":"e_1_2_6_22_2","first-page":"412","article-title":"Homeostasis model assessment","volume":"28","author":"Matthews D","year":"1985","journal-title":"insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031503"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1921"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2007.20.2.187"},{"key":"e_1_2_6_26_2","first-page":"314","article-title":"Indexes of insulin resistance and secretion in obese children and adolescents","volume":"27","author":"Conwell L","year":"2004","journal-title":"a validation study"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.11.2081"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131334.38172.01"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1610-y"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/135965350701200811","article-title":"Lipodystrophy and metabolic changes in HIV\u2010infected children on non\u2010nucleoside reverse transcriptase inhibitor\u2010based antiretroviral therapy","volume":"12","author":"Aurpibul L","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_6_32_2","first-page":"726","article-title":"An objective case definition of lipodystrophy in HIV\u2010infected adults","volume":"361","author":"Carr A","year":"2003","journal-title":"a case\u2013control study"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00012"},{"key":"e_1_2_6_34_2","first-page":"395","article-title":"Redefining lipodystrophy syndrome","volume":"39","author":"Lichtenstein K.","year":"2005","journal-title":"risks and impact on clinical decision making"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012578"},{"issue":"12","key":"e_1_2_6_36_2","first-page":"1","article-title":"1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age","volume":"43","author":"Centers for Disease Control and Prevention","year":"1994","journal-title":"MMWR"},{"key":"e_1_2_6_37_2","unstructured":"Working Group on Antiretroviral Therapy and Medical Management of HIV\u2010Infected Children.Guidelines for the use of antiretroviral agents in pediatric HIV infection Supp III: adverse drug effects. Bethesda MD:US Department of Health and Human Services2006 30 pp."},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0414"},{"key":"e_1_2_6_39_2","first-page":"713","article-title":"Antiretroviral therapy in HIV\u2010infected children","volume":"19","author":"Leonard E","year":"2005","journal-title":"the metabolic cost of improved survival"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02223.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000147527.64863.1a"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922201316912727"},{"key":"e_1_2_6_43_2","first-page":"e275","article-title":"Impact of protease inhibitor substitution with efavirenz in HIV\u2010infected children","volume":"111","author":"McComsey G","year":"2003","journal-title":"results of the First Pediatric Switch Study"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000257427.19764.ff"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.2.e25"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1079\/BJN20061754"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114507793959"},{"key":"e_1_2_6_48_2","first-page":"250","article-title":"C\u2010peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta\u2010cell function","volume":"53","author":"Palmer J","year":"2004","journal-title":"report of an ADA Workshop, 21\u201322 October 2001"},{"key":"e_1_2_6_49_2","volume-title":"Antiretroviral therapy for HIV infections in adults and adolescents in resource\u2010limited settings: recommendations for a public health approach. 2006 rev","author":"World Health Organization","year":"2006"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00653.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00653.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:45:13Z","timestamp":1696866313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00653.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,20]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00653.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00653.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,20]]}}}